Xiya Reagent:Juno expands its CAR-T arsenal with latest immuno-o

Juno expands its CAR-T arsenal with latest immuno-oncology deal

Seattle's Juno Therapeutics, at work on treatments that train the immune system to better fight cancer, has signed a deal to expand its pipeline of therapies, licensing a complementary candidate developed by the National Cancer Institute.

Under a deal with NCI partner Opus Bio, Juno has paid an undisclosed sum to license an immunotherapy that targets CD22, a protein expressed on B cell leukemias and lymphomas. Juno's work in the field has thus far focused on CD19, another protein common among blood cancers.

Much like the rest of Juno's pipeline, the NCI treatment is a CAR-T immunotherapy, in which scientists remove T cells from a patient's blood and equip them with targeting mechanisms called chimeric antigen receptors (CARs), which seek out and bind to proteins expressed by cancer cells. The resulting cells are reinjected into the patient, at which point they track down malignancies and attack them as they would any commonplace infection.

NCI, in collaboration with Opus, has already begun enrollment in Phase I study testing the candidate in children and adolescents with relapsed/refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL· 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   

· 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇氯甲基甲醚 等均有销售.欢迎订购